Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637705 | 0.82 | P2RX7 (0.53) | P2RX7SSTR4 | |
| SCHEMBL1636744 | 0.82 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL1636710 | 0.82 | P2RX7 (0.57) | P2RX7 | |
| SCHEMBL1637480 | 0.80 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL1637645 | 0.76 | P2RX7 (0.56) | P2RX7 | |
| SCHEMBL1636796 | 0.76 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL1636732 | 0.76 | P2RX7 (0.45) | P2RX7 | |
| SCHEMBL1636701 | 0.75 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL1637472 | 0.74 | P2RX7 (0.53) | P2RX7SSTR4 | |
| SCHEMBL1637704 | 0.74 | P2RX7 (0.48) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932282-B2 | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| CN-101679291-A | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX5 | P2RX7 2/4885HDAC1 1558/4885HDAC8 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.